- $4.77bn
- $4.66bn
- $1.04bn
- 96
- 25
- 97
- 84
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 696 | 771 | 874 | 991 | 1,038 |
Cost of Revenue | |||||
Gross Profit | 481 | 546 | 625 | 738 | 777 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 836 | 808 | 902 | 954 | 987 |
Operating Profit | -139 | -37.6 | -27.6 | 36.8 | 50.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -143 | -42.2 | -37.5 | 34.4 | 62.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -144 | -43.4 | -41.5 | 26.8 | 129 |
Net Income Before Extraordinary Items | |||||
Net Income | -144 | -43.4 | -41.5 | 26.8 | 129 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -144 | -43.4 | -53.9 | 8.57 | 99.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.97 | -0.27 | -0.341 | 0.061 | 0.673 |